Robbie Huffines
INSULETAbout Robbie Huffines
Independent director at Insulet (PODD), appointed effective October 31, 2025, and a member of the Audit Committee. Former Global Chair of Investment Banking at J.P. Morgan (2020–2024), with three decades advising healthcare companies; prior roles include Vice Chair of Investment Banking and co-head of Global Healthcare IB. He holds an MBA from the University of Virginia Darden School and a BA in English/Economics from the University of North Carolina. Tenure at Insulet began October 31, 2025; independence affirmed in the appointment 8-K and press release.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| J.P. Morgan Chase & Co. | Global Chair of Investment Banking; member, Executive Committee | 2020–2024 | Led strategic coverage across sectors, with deep healthcare M&A and financing experience |
| J.P. Morgan Chase & Co. | Vice Chairman of Investment Banking | 2011–2020 | Senior client coverage and advisory leadership |
| J.P. Morgan Chase & Co. | Co-head, Global Healthcare Investment Banking | 2002–2010 | Built and led healthcare IB franchise globally |
| J.P. Morgan (M&A Group) | Healthcare M&A banker | Joined 1992 | Advised on mergers, divestitures, financing across healthcare |
| Alex. Brown & Sons | Equity financing and advisory (emerging growth) | Pre-1992 | Early-stage equity capital markets/advisory experience |
External Roles
| Organization | Role | Status / Tenure | Committees/Notes |
|---|---|---|---|
| Becton, Dickinson and Company (BDX) | Director (independent) | Effective Dec 1, 2025 | Audit; Corporate Governance & Nominating committees |
| Walgreens Boots Alliance | Director (former) | Served until company sale in Aug 2025 | Ended upon transaction close |
| Eikon Therapeutics | Director | Current | Private biotech; board service disclosed in Insulet 8-K |
| Nextech Invest Ltd. | Director | Current | Cancer-focused investment firm (Zurich) |
| The Hastings Center (Biomedical Ethics) | Director | Current | Nonprofit board service |
| The Forest Group (nonprofit) | Co-founder | Since 2023 | Youth mental health; nonprofit |
Board Governance
- Committee assignment: Audit Committee member at Insulet (independent). Audit Committee held 7 meetings in FY2024; the Board met 5 times in 2024. All directors then in office attended 100% of Board and committee meetings; Huffines joined in Oct 2025 (no attendance history yet).
- Independence: Appointed as an independent director; Insulet’s statutory committees are composed solely of independent directors per proxy.
- Overboarding policy: Non-CEO directors should not serve on more than five public company boards (inclusive of Insulet). Current public-company seats: Insulet and BD (2 total) — within policy.
- Executive sessions and governance practices: Regular executive sessions of independent directors; robust ownership guidelines; no hedging or pledging permitted for directors.
- ESG/cyber oversight: The Nominating, Governance & Risk Committee oversees ESG and cybersecurity; Audit oversees financial reporting/internal controls.
Fixed Compensation
| Component | Policy Detail | Amount |
|---|---|---|
| Annual Board retainer (cash) | Non-employee director annual cash retainer | $70,000 |
| Committee member retainers (cash) | Audit Committee member | $12,500 |
| Committee chair retainers (cash) | Audit Chair (not applicable to Huffines) | $25,000 |
| Equity – Initial Award | New directors receive RSUs on joining; vests 50%/25%/25% on anniversary dates | $300,000 grant-date fair value |
| Equity – Annual Award | RSUs granted at each Annual Meeting; vest fully the following April 30 | $250,000 grant-date fair value |
| Deferred compensation | Directors may elect to defer cash fees and/or settlement of RSUs | Plan available; individual elections disclosed for 2024 for other directors |
| Non-employee director compensation limit | Maximum total annual compensation (cash + equity) | $900,000; $1,500,000 in year first joining or serving as Chair/Lead |
Per the 8-K, Huffines will receive cash and equity compensation pursuant to Insulet’s non-employee director program; specific 2025 amounts will be disclosed in the next proxy.
Performance Compensation
| Performance Linkage in Director Pay | Details |
|---|---|
| None (time-based only) | Non-employee director RSUs vest based on time; no performance metrics (no PSUs/options for directors in the standard program). |
Other Directorships & Interlocks
| Company | Overlap/Interlock Considerations |
|---|---|
| BD (BDX) | Large diversified medtech; as of disclosure, no related-party transactions reported between Insulet and Huffines; monitor for any vendor/customer relationships given overlapping sector. |
| Walgreens Boots Alliance (former) | Ended Aug 2025 with company sale; no ongoing interlock. |
- Compensation Committee interlocks (Insulet): Company disclosed no 2024 interlocks/insider participation for its Talent & Compensation Committee. Huffines is not on this committee.
Expertise & Qualifications
- Capital markets/M&A: Three decades in healthcare investment banking; former Global Chair of IB at J.P. Morgan.
- Governance and audit oversight: Audit Committee member at Insulet and BD; extensive financial and strategic advisory background.
- Education: MBA (UVA Darden); BA (UNC).
Equity Ownership
| As of | Beneficial Shares | Ownership Form | Derivative Securities | Notes |
|---|---|---|---|---|
| Oct 31, 2025 (Form 3 event date) | 0 | Direct | None reported | Initial statement of beneficial ownership filed Nov 3, 2025. |
- Stock ownership guidelines for directors: 5× annual cash retainer (increased in May 2024). Anti-hedging and anti-pledging apply to directors. As a new director with 0 shares at appointment, Huffines is not yet at guideline; expected to build holdings via initial/annual RSUs under the program.
Governance Assessment
- Positives
- Independence and immediate placement on Audit Committee; strengthens financial oversight with deep healthcare deal/strategy expertise.
- No related-party transactions requiring disclosure under Item 404(a) at appointment (conflict check).
- Strong board governance framework: director overboarding limits, robust ownership guidelines, and prohibition on hedging/pledging.
- Board/committee engagement culture: 100% attendance by 2024 directors; regular executive sessions.
- Watch items
- Time commitments: Will serve on two public boards (PODD and BDX); within policy but should be monitored alongside other nonprofit/private commitments.
- Sector overlap: BD is a broad medtech company; monitor for future related-party transactions or competitive/supplier overlaps; none disclosed at appointment.
Related-Party and Conflict Checks
- Insulet 8-K states no transactions involving Huffines require disclosure under Item 404(a), and no arrangements/understandings pursuant to which he was selected.
Insider Filings
| Filing | Date Filed | Event Date | Summary |
|---|---|---|---|
| Form 3 | Nov 3, 2025 | Oct 31, 2025 | Initial statement; 0 common shares beneficially owned; director status. |
Notes on Compensation Framework (context for alignment)
- Non-employee director program benchmarked and increased in 2024 (Board retainer +$10k; Chair retainer +$37.5k), indicating market alignment and governance refresh, with clear limits in the 2025 equity plan.
- Executive pay metrics (for context, not applicable to directors): Adjusted Revenue and Adjusted EBIT are primary measures for NEO incentives; not used for directors.